Kexing Biopharm Co.,Ltd.(688136),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

688136 Kexing Biopharm Co.,Ltd.

Closed 04-02 15:00:01

32.72

+1.34

+4.27%

High33.72	Low30.90	Vol14.48M
Open30.90	D1 Closing31.38	Amplitude8.99%
Mkt Cap6.58B	Tradable Cap6.58B	Total Shares201.00M
T/O466.00M	T/O Rate7.20%	Tradable Shares201.00M
P/B3.84	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688136","market":"SH","secType":"STK","nameCN":"Kexing Biopharm Co.,Ltd.","latestPrice":32.72,"timestamp":1775113201000,"preClose":31.38,"halted":0,"volume":14478213,"delay":0,"changeRate":0.0427,"floatShares":200999999,"shares":200999999,"eps":0.624,"marketStatus":"Closed","change":1.34,"latestTime":"04-02 15:00:01","open":30.9,"high":33.72,"low":30.9,"amount":466000000,"amplitude":0.0899,"askPrice":32.73,"askSize":90,"bidPrice":32.72,"bidSize":367,"shortable":0,"etf":0,"ttmEps":0.624,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775179800000},"marketStatusCode":5,"adr":0,"adjPreClose":31.38,"symbolType":"stock_kcb","openAndCloseTimeList":[[1775093400000,1775100600000],[1775106000000,1775113200000]],"highLimit":34.52,"lowLimit":28.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201257250,"isCdr":false,"pbRate":3.84,"roa":"--","peRate":52.435897,"roe":"6.66%","epsLYR":0.16,"committee":0.597561,"marketValue":6585000000,"turnoverRate":0.0719,"status":0,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-04-08.","afterMarket":{"amount":0,"volume":0,"close":32.72,"buyVolume":0,"sellVolume":0,"time":1775115237919,"indexStatus":"Closed 04-02 15:30:00","preClose":31.38},"floatMarketCap":6585000000},"requestUrl":"/m/hq/s/688136/wiki","defaultTab":"wiki","newsList":[{"id":"1123249834","title":"Biopharmaceutical Stocks Experience Downturn, Kexing Biopharm Leads Declines with Over 10% Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=1123249834","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123249834?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:40","pubTimestamp":1773902433,"startTime":"0","endTime":"0","summary":"On March 19, the innovative drug sector in the A-share market faced volatility and a downward trend. Kexing Biopharm Co.,Ltd. saw a decline of over 10%, leading the losses. Other notable decliners...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","399300","BK0239","159992","BK1574","159982","688136","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616785534","title":"Kexing Biopharm Gets Clinical Trial Approval for Lupus Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2616785534","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616785534?lang=en_us&edition=fundamental","pubTime":"2026-03-04 19:42","pubTimestamp":1772624531,"startTime":"0","endTime":"0","summary":"Kexing Biopharm  unit obtained the approval to start clinical trials for GB19 injection to treat cutaneous lupus erythematosus.The approval was granted by China's drug administrator, according to a Wednesday filing with the Shanghai bourse.Shares of the biopharmaceutical company closed 1% lower.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152589531","title":"Kexing Biopharm's GB19 Injection Receives Clinical Trial Approval for Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=1152589531","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152589531?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:20","pubTimestamp":1772536816,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co., Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616734865","title":"Kexing Biopharm Renews Related-Party Agreements for Shenzhen Property","url":"https://stock-news.laohu8.com/highlight/detail?id=2616734865","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616734865?lang=en_us&edition=fundamental","pubTime":"2026-03-03 16:23","pubTimestamp":1772526225,"startTime":"0","endTime":"0","summary":"Kexing Biopharm  renewed its office lease and property management agreements with Chuangyi Biotech for the Chuangyi Technology Building in Shenzhen.The two-year contract is effective March 1, according to a Tuesday filing with the Shanghai bourse. Total rent is capped at 17.1 million yuan, with property management fees of up to 3.1 million over the term.Kexing Biopharm and Chuangyi Biotech are controlled by Zhengzhong Investment Group.Shares of the biopharmaceutical company closed 4% lower Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688136","BK0239","CFA.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614704918","title":"Kexing Biopharm Gets China Nod for Lupus Drug Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2614704918","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614704918?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109042,"startTime":"0","endTime":"0","summary":"China's drug regulator approved a planned clinical trial by Kexing Biopharm  subsidiary Shenzhen Sinovac Pharmaceutical for its GB19 injection, according to a Thursday filing with the Shanghai bourse.The GB19 injection is seen to help treat various autoimmune diseases such as systemic lupus erythematosus, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128782685","title":"Kexing Biopharm (688136.SH): Ophthalmic Formulation GB10 Injection Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1128782685","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128782685?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:00","pubTimestamp":1765191621,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), recently received the \"Drug Clinical Trial Approval...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164311679","title":"Former Construction Bureau Deputy Director Ventures into Pharma, Kexing Biopharm's Major Shareholder Cashes Out 1 Billion Before IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1164311679","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164311679?lang=en_us&edition=fundamental","pubTime":"2025-11-24 18:21","pubTimestamp":1763979674,"startTime":"0","endTime":"0","summary":"When people hear \"Kexing,\" many first think of Sinovac Biotech (SVA.O), the global star pharmaceutical company that made a fortune with its COVID-19 vaccine. However, in the capital markets, there is...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584606649","title":"Kexing Biopharm Seeks China Approval for Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584606649","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584606649?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:06","pubTimestamp":1763427997,"startTime":"0","endTime":"0","summary":"Kexing Biopharm  is seeking approval from Chinese regulators for its share listing in Hong Kong, according to a Tuesday filing with the Shanghai bourse.The biotechnology products developer's listing is still subject to approval by regulators in Hong Kong and mainland China, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194507103","title":"Kexing Biopharm Co.,Ltd. (688136.SH): Keying Medicine Plans to Transfer 5% Stake via Inquiry","url":"https://stock-news.laohu8.com/highlight/detail?id=1194507103","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194507103?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:22","pubTimestamp":1763122929,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co.,Ltd. (688136.SH) disclosed a shareholder inquiry-based transfer plan. The participating shareholder, Keying Medicine, intends to transfer 10.0628 million shares, representing 5% of the company's total equity.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK1515","BK0239","BK1161","159938","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583508704","title":"BRIEF-Kexing Biopharm's Shareholder To Sell 5.0% Stake In Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508704","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508704?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:58","pubTimestamp":1763121517,"startTime":"0","endTime":"0","summary":"BRIEF-Kexing Biopharm's Shareholder To Sell 5.0% Stake In CoNov 14  - Kexing Biopharm Co Ltd 688136.SS:SAYS SHAREHOLDER PLANS TO SELL 5.0% STAKE IN CO VIA INQUIRY-BASED TRANSFERSource textFurther company coverage: 688136.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL4N3WQ0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583350816","title":"Kexing Biopharm  Says Shareholder Plans to Sell 5.0% Stake in Co via Inquiry-Based Transfer","url":"https://stock-news.laohu8.com/highlight/detail?id=2583350816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583350816?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:58","pubTimestamp":1763121517,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL4N3WQ0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581116073","title":"Kexing Biopharm Files for Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2581116073","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581116073?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:33","pubTimestamp":1762497186,"startTime":"0","endTime":"0","summary":"Kexing Biopharm  submitted documents for its planned initial public offering on the Hong Kong Stock Exchange, according to a Friday disclosure to the Shanghai bourse.The biopharmaceutical company intends to use the IPO proceeds for research and development, biosimilar drug screening and development, introduction of new pharmaceutical products, establishment of a marketing team, and working capital.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128910002","title":"Kexing Biopharm (688136.SH) Submits H-Share Listing Application to HKEX and Publishes Application Materials","url":"https://stock-news.laohu8.com/highlight/detail?id=1128910002","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128910002?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:06","pubTimestamp":1762427176,"startTime":"0","endTime":"0","summary":"Kexing Biopharm Co., Ltd. (688136.SH) announced that on November 6, 2025, it submitted an application to The Stock Exchange of Hong Kong Limited (HKEX) for the issuance of H-shares and listing on the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579646351","title":"Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at Cphi Frankfurt 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579646351","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579646351?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:10","pubTimestamp":1761909003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUA4ZZZFZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688136","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-12-14","address":"山东省济南市章丘区埠村街道创业路2666号","stockEarnings":[{"period":"1week","weight":0.2943},{"period":"1month","weight":0.1429},{"period":"3month","weight":0.0332},{"period":"6month","weight":-0.1615},{"period":"1year","weight":0.13},{"period":"ytd","weight":0.0332}],"companyName":"科兴生物制药股份有限公司","boardCode":"AI0027","perCapita":"17102股","boardName":"医药制造业","registeredCapital":"20125万元","compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":-0.0493},{"period":"3month","weight":-0.0125},{"period":"6month","weight":0.0094},{"period":"1year","weight":0.1699},{"period":"ytd","weight":-0.0125}],"survey":"　　科兴生物制药股份有限公司的主营业务是重组蛋白药物和微生态制剂的研发、生产、销售。公司的主要产品是依普定、赛若金、白特喜、常乐康。","serverTime":1775149845783,"listedPrice":22.33,"stockholders":"11768人(较上一季度增加25.03%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kexing Biopharm Co.,Ltd.(688136),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kexing Biopharm Co.,Ltd.(688136) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kexing Biopharm Co.,Ltd.,688136,Kexing Biopharm Co.,Ltd.股票,Kexing Biopharm Co.,Ltd.股票老虎,Kexing Biopharm Co.,Ltd.股票老虎国际,Kexing Biopharm Co.,Ltd.行情,Kexing Biopharm Co.,Ltd.股票行情,Kexing Biopharm Co.,Ltd.股价,Kexing Biopharm Co.,Ltd.股市,Kexing Biopharm Co.,Ltd.股票价格,Kexing Biopharm Co.,Ltd.股票交易,Kexing Biopharm Co.,Ltd.股票购买,Kexing Biopharm Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kexing Biopharm Co.,Ltd.(688136),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kexing Biopharm Co.,Ltd.(688136) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction